Liminal Biosciences Inc (DELISTED) (LMNL:DL)
8.50
0.00 (0.00%)
USD |
NASDAQ |
Sep 26, 16:00
Liminal Biosciences Max Drawdown (5Y)
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
September 30, 2023 | 99.97% |
August 31, 2023 | 99.97% |
July 31, 2023 | 99.97% |
June 30, 2023 | 99.97% |
May 31, 2023 | 99.97% |
April 30, 2023 | 99.97% |
March 31, 2023 | 99.97% |
February 28, 2023 | 99.97% |
January 31, 2023 | 99.97% |
December 31, 2022 | 99.97% |
November 30, 2022 | 99.97% |
October 31, 2022 | 99.97% |
September 30, 2022 | 99.97% |
August 31, 2022 | 99.97% |
July 31, 2022 | 99.97% |
June 30, 2022 | 99.97% |
May 31, 2022 | 99.97% |
April 30, 2022 | 99.95% |
March 31, 2022 | 99.95% |
February 28, 2022 | 99.95% |
January 31, 2022 | 99.95% |
December 31, 2021 | 99.95% |
November 30, 2021 | 99.93% |
October 31, 2021 | 99.91% |
September 30, 2021 | 99.91% |
Date | Value |
---|---|
August 31, 2021 | 99.91% |
July 31, 2021 | 99.88% |
June 30, 2021 | 99.86% |
May 31, 2021 | 99.86% |
April 30, 2021 | 99.86% |
March 31, 2021 | 99.86% |
February 28, 2021 | 99.86% |
January 31, 2021 | 99.86% |
December 31, 2020 | 99.86% |
November 30, 2020 | 99.86% |
October 31, 2020 | 99.83% |
September 30, 2020 | 99.80% |
August 31, 2020 | 99.80% |
July 31, 2020 | 99.80% |
June 30, 2020 | 99.80% |
May 31, 2020 | 99.80% |
April 30, 2020 | 99.80% |
March 31, 2020 | 99.80% |
February 29, 2020 | 99.79% |
January 31, 2020 | 99.79% |
December 31, 2019 | 99.79% |
November 30, 2019 | 99.79% |
October 31, 2019 | 99.79% |
September 30, 2019 | 99.79% |
August 31, 2019 | 99.79% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
98.91%
Minimum
May 2019
99.97%
Maximum
Oct 2022
99.86%
Average
99.88%
Median
Jul 2021
Max Drawdown (5Y) Benchmarks
Acasti Pharma Inc | 98.73% |
Aurinia Pharmaceuticals Inc | 87.58% |
Edesa Biotech Inc | 99.58% |
Lexaria Bioscience Corp | 98.90% |
Xenon Pharmaceuticals Inc | 64.74% |